BioNxt Solutions develops precision transdermal and oral drug formulations, along with point-of-care diagnostics for rapid infectious disease screening. Their technologies aim to enhance treatment efficacy and accessibility for neurological diseases and mental health conditions, including depression and PTSD.
Funding
$270K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective treatments for neurological diseases and mental health conditions like depression, PTSD, and multiple sclerosis is challenging due to inefficient drug delivery methods and the need for rapid, accessible diagnostic tools. Current drug formulations often lack targeted delivery and bioavailability, while point-of-care diagnostics require faster and more accurate screening for early detection and better treatment outcomes.
Solution
BioNxt Solutions addresses these challenges by developing innovative precision transdermal and oral drug formulations alongside point-of-care diagnostics for rapid infectious disease screening. The company focuses on enhancing treatment efficacy and accessibility through advanced drug delivery methods, including transdermal patches and sublingual thin-films, designed for efficient and affordable treatment of neurological diseases, autoimmune diseases, and mental health conditions. BioNxt's research and development efforts also extend to the production, formulation, and validation of new active pharmaceutical ingredients (APIs), as well as rapid testing and biosensors for early disease detection. By combining cutting-edge drug delivery technologies with accessible diagnostic tools, BioNxt aims to improve patient outcomes and quality of life.
Target Audience
BioNxt Solutions targets individuals suffering from neurological diseases, mental health conditions, and autoimmune disorders, as well as healthcare providers seeking advanced drug delivery methods and rapid diagnostic tools.
Features
- Development of transdermal patches for precise and controlled drug release.
- Sublingual thin-film technology for rapid drug absorption and improved bioavailability.
- Point-of-care diagnostics for rapid and accurate infectious disease screening.
- Production and validation of new active pharmaceutical ingredients (APIs).
- Focus on treatments for neurological diseases, autoimmune diseases, and mental health conditions.
- Pipeline includes BNT23001 for Multiple Sclerosis, BNT23002 for Myasthenia Gravis, BNT24002 for Lupus Nephritis, BNT24003 for Rheumatoid Arthritis and BNT24004 for longevity.
- Development of psychedelic drug formulations.